OBJECTIVES: There is currently much interest in biomarkers of disease activity in frontotemporal lobar degeneration (FTLD). We assessed MRI and behavioral measures of progression in a longitudinal FTLD cohort. METHODS: Thirty-two patients with FTLD (11 behavioral variant frontotemporal dementia [bvFTD], 11 semantic dementia [SemD], 10 progressive nonfluent aphasia [PNFA]) and 24 age-matched healthy controls were assessed using volumetric brain MRI and standard behavioral measures (Mini-Mental State Examination, Frontal Assessment Battery, Clinical Dementia Rating Scale, Neuropsychiatric Inventory with Caregiver Distress scale) at baseline and 1 year later. A semi-automated image registration protocol was used to calculate annualized rates of brain atrophy (brain boundary shift integral [BBSI]) and ventricular expansion (ventricular boundary shift integral [VBSI]). Associations between these rates and changes in behavioral indices were investigated. RESULTS: Rates of whole brain atrophy were greater in the entire FTLD cohort and in each subgroup compared with controls (all p < or = 0.004). Rates of ventricular expansion were greater in the entire cohort (p < 0.001) and the SemD (p = 0.002) and PNFA (p = 0.05) subgroups compared with controls. Changes in Mini-Mental State Examination, Frontal Assessment Battery, and Clinical Dementia Rating Scale scores were associated with MRI measures of progression, though not uniformly across FTLD subgroups. Both BBSI and VBSI yielded feasible sample size estimates for detecting meaningful treatment effects in SemD and PNFA language subgroups. Sample sizes were substantially larger using MRI biomarkers for the bvFTD subgroup, and using behavioral biomarkers in general. CONCLUSIONS: Semi-automated MRI atrophy measures are potentially useful objective biomarkers of progression in frontotemporal lobar degeneration (FTLD); however, careful stratification of FTLD subtypes will be important in future clinical trials of disease-modifying therapies.
OBJECTIVES: There is currently much interest in biomarkers of disease activity in frontotemporal lobar degeneration (FTLD). We assessed MRI and behavioral measures of progression in a longitudinal FTLD cohort. METHODS: Thirty-two patients with FTLD (11 behavioral variant frontotemporal dementia [bvFTD], 11 semantic dementia [SemD], 10 progressive nonfluent aphasia [PNFA]) and 24 age-matched healthy controls were assessed using volumetric brain MRI and standard behavioral measures (Mini-Mental State Examination, Frontal Assessment Battery, Clinical Dementia Rating Scale, Neuropsychiatric Inventory with Caregiver Distress scale) at baseline and 1 year later. A semi-automated image registration protocol was used to calculate annualized rates of brain atrophy (brain boundary shift integral [BBSI]) and ventricular expansion (ventricular boundary shift integral [VBSI]). Associations between these rates and changes in behavioral indices were investigated. RESULTS: Rates of whole brain atrophy were greater in the entire FTLD cohort and in each subgroup compared with controls (all p < or = 0.004). Rates of ventricular expansion were greater in the entire cohort (p < 0.001) and the SemD (p = 0.002) and PNFA (p = 0.05) subgroups compared with controls. Changes in Mini-Mental State Examination, Frontal Assessment Battery, and Clinical Dementia Rating Scale scores were associated with MRI measures of progression, though not uniformly across FTLD subgroups. Both BBSI and VBSI yielded feasible sample size estimates for detecting meaningful treatment effects in SemD and PNFA language subgroups. Sample sizes were substantially larger using MRI biomarkers for the bvFTD subgroup, and using behavioral biomarkers in general. CONCLUSIONS: Semi-automated MRI atrophy measures are potentially useful objective biomarkers of progression in frontotemporal lobar degeneration (FTLD); however, careful stratification of FTLD subtypes will be important in future clinical trials of disease-modifying therapies.
Authors: Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers Journal: Alzheimer Dis Assoc Disord Date: 2006 Jan-Mar Impact factor: 2.703
Authors: Keith A Josephs; Joseph R Duffy; Edyth A Strand; Jennifer L Whitwell; Kenneth F Layton; Joseph E Parisi; Mary F Hauser; Robert J Witte; Bradley F Boeve; David S Knopman; Dennis W Dickson; Clifford R Jack; Ronald C Petersen Journal: Brain Date: 2006-04-13 Impact factor: 13.501
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: David S Knopman; Joel H Kramer; Bradley F Boeve; Richard J Caselli; Neill R Graff-Radford; Mario F Mendez; Bruce L Miller; Nathaniel Mercaldo Journal: Brain Date: 2008-10-01 Impact factor: 13.501
Authors: D S Knopman; C R Jack; J H Kramer; B F Boeve; R J Caselli; N R Graff-Radford; M F Mendez; B L Miller; N D Mercaldo Journal: Neurology Date: 2009-05-26 Impact factor: 9.910
Authors: M L Gorno-Tempini; S M Brambati; V Ginex; J Ogar; N F Dronkers; A Marcone; D Perani; V Garibotto; S F Cappa; B L Miller Journal: Neurology Date: 2008-07-16 Impact factor: 9.910
Authors: Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs Journal: Brain Date: 2007-03-08 Impact factor: 13.501
Authors: J D Rohrer; E McNaught; J Foster; S L Clegg; J Barnes; R Omar; E K Warrington; M N Rossor; J D Warren; N C Fox Journal: Neurology Date: 2008-10-28 Impact factor: 9.910
Authors: Jonathan Beck; Jonathan D Rohrer; Tracy Campbell; Adrian Isaacs; Karen E Morrison; Emily F Goodall; Elizabeth K Warrington; John Stevens; Tamas Revesz; Janice Holton; Safa Al-Sarraj; Andrew King; Rachael Scahill; Jason D Warren; Nick C Fox; Martin N Rossor; John Collinge; Simon Mead Journal: Brain Date: 2008-01-29 Impact factor: 13.501
Authors: Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Matthew L Senjem; Bradley F Boeve; David S Knopman; Glenn E Smith; Robert J Ivnik; Clifford R Jack; Ronald C Petersen Journal: Brain Date: 2011-01-20 Impact factor: 13.501
Authors: Johannes Brettschneider; Kelly Del Tredici; David J Irwin; Murray Grossman; John L Robinson; Jon B Toledo; Lubin Fang; Vivianna M Van Deerlin; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-01-10 Impact factor: 17.088
Authors: Lars Frings; Irina Mader; Bernhard G Landwehrmeyer; Cornelius Weiller; Michael Hüll; Hans-Jürgen Huppertz Journal: Hum Brain Mapp Date: 2011-05-26 Impact factor: 5.038
Authors: Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings Journal: Alzheimers Dement Date: 2012-10-10 Impact factor: 21.566